m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05967
 [1]
m6A modification CCAT2 CCAT2 VIRMA Methylation : m6A sites Indirect Inhibition Non-coding RNA miR-145 MYC  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Protein virilizer homolog (VIRMA) WRITER
 Regulator Info 
m6A Target Colon cancer associated transcript 2 (CCAT2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 145 (MIR145) microRNA View Details
Regulated Target Myc proto-oncogene protein (MYC) View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators indirectly modulate the functionality of ncRNAs through downstream signaling pathways
Crosstalk Summary In prostate cancer, VIRMA-mediated m6A modification of Colon cancer associated transcript 2 (CCAT2) can upregulate CCAT2, which act as a sponge for MIR145 to upregulate the expression of Myc proto-oncogene protein (MYC).
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
Responsed Drug Actinomycin D
 Drug Info 
Cell Process RNA stability
In-vitro Model
 22Rv1 Prostate carcinoma Homo sapiens CVCL_1045
LNCaP Prostate carcinoma Homo sapiens CVCL_0395
VCaP Prostate carcinoma Homo sapiens CVCL_2235
DU145 Prostate carcinoma Homo sapiens CVCL_0105
PC-3 Prostate carcinoma Homo sapiens CVCL_0035
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Myc proto-oncogene protein (MYC) 3 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name AVI-5126 Phase 2 [2]
Synonyms
Resten-CP; NeuGene (CABG), AVI
    Click to Show/Hide
External Link
TTD: D01VDI
 Compound Name Resten-NG Phase 2 [3]
Synonyms
Resten-NG (TN)
    Click to Show/Hide
External Link
TTD: D0M4MG
 Compound Name TWS-119 Investigative [4]
Synonyms
TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
    Click to Show/Hide
External Link
CID: 9549289
TTD: D0T8KR
2C82: Prostate cancer 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name CC-94676 Phase 1 [5]
External Link
TTD: DNY63Z
References
Ref 1 VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. Cancers (Basel). 2020 Mar 25;12(4):771. doi: 10.3390/cancers12040771.
Ref 2 Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. doi: 10.1089/jop.2011.0135. Epub 2011 Dec 7.
Ref 3 Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 4 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 5 ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.